# CER-1236 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cer-1236

> CER-1236, sponsored by CERO THERAPEUTICS HOLDINGS, INC. (CERO): 5 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CER-1236 |
| Codes | CER-1236 |
| Sponsor | CERO THERAPEUTICS HOLDINGS, INC. (CERO) https://sec-api.dev/companies/cero/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan, priority review, rmat |

## Timeline

### June 28, 2024: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2024-12-23, last confirmed 2025-07-21.
- SEC registration statement (S-1) (accession 0001213900-25-066152): "On June 28, 2024, the Company submitted an Investigational New Drug Application ("IND") for its product candidate, CER-1236, to FDA." https://www.sec.gov/Archives/edgar/data/1870404/000121390025066152/ea0244907-s1_cero.htm
- SEC Form 10-Q (accession 0001213900-25-044335): "On June 28, 2024, the Company submitted an Investigational New Drug Application ("IND") for its product candidate, CER-1236, to FDA." https://www.sec.gov/Archives/edgar/data/1870404/000121390025044335/ea0241691-10q_cero.htm
- SEC Form 10-K (accession 0001213900-25-032134): "On June 28, 2024, the Company submitted an Investigational New Drug Application ("IND") for its product candidate, CER-1236, to FDA." https://www.sec.gov/Archives/edgar/data/1870404/000121390025032134/ea0237245-10k_cero.htm
- SEC registration statement (S-1) (accession 0001213900-24-111475): "On June 28, 2024, the Company submitted an Investigational New Drug Application ("IND") for its product candidate, CER-1236, to FDA." https://www.sec.gov/Archives/edgar/data/1870404/000121390024111475/ea0225388-s1_cero.htm

### 1H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2024-12-06, last confirmed 2024-12-06.
- Press release filed with the SEC (EX-99) (accession 0001213900-24-106240): "As we draw closer to introducing CER-1236 into the clinic, we continue to make additional pre-clinical progress with CER-1236 and presently intend to file an additional Investigational New Drug Application for CER-1236 in solid tumors, including ovarian and non-small cell lung cancers, in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390024106240/ea022355901ex99-1_cero.htm

### Q1 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2024-11-18, last confirmed 2024-11-18.
- Press release filed with the SEC (EX-99) (accession 0001213900-24-099354): "Now this team will turn its attention to expeditiously deploying our resources in anticipation of what we believe will be a first quarter 2025 start for our Phase 1 trial, and we look forward to sharing future program updates," concluded Ehrlich." https://www.sec.gov/Archives/edgar/data/1870404/000121390024099354/ea022142102ex99-1_cero.htm

### May 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-07-21, last confirmed 2026-04-15.
- SEC Form 10-K (accession 0001213900-26-044040): "Based on the preclinical data regarding the use of CER-1236 T cells to combat hematologic malignancies, we began our Phase 1 clinical trial in May 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/ea0285271-10k_cero.htm
- SEC Form 10-K (accession 0001213900-26-044040): "We began dosing the cohort in our Phase 1 AML clinical trial of CER-1236 in May 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/ea0285271-10k_cero.htm
- SEC Form 10-K (accession 0001213900-26-044040): "Based on the extensive preclinical data that we have assembled regarding the use of CER-1236 T cells to combat cancer, we commenced our Phase 1 clinical trial in May 2025 with an initial treatment target being patients suffering from relapsed, or refractory AML as well as those subsets who are positive for" https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/ea0285271-10k_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-118817): "Based on the preclinical data regarding the use of CER-1236 T cells to combat hematologic malignancies, we began our Phase 1 clinical trial in May 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390025118817/ea0267089-s1_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-118817): "We began dosing the cohort in our Phase 1 AML clinical trial of CER-1236 in May 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390025118817/ea0267089-s1_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-118817): "Based on the extensive preclinical data that we have assembled regarding the use of CER-1236 T cells to combat cancer, we commenced our Phase 1 clinical trial in May 2025 with an initial treatment target being patients suffering from relapsed, or refractory AML as well as those subsets who are positive for" https://www.sec.gov/Archives/edgar/data/1870404/000121390025118817/ea0267089-s1_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-066152): "Based on the preclinical data regarding the use of CER-1236 T cells to combat hematologic malignancies, we began our Phase 1 clinical trial in May 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390025066152/ea0244907-s1_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-066152): "We dosed the first patient in our Phase 1 AML clinical trial of CER-1236 in May 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390025066152/ea0244907-s1_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-066152): "Based on the extensive preclinical data that we have assembled regarding the use of CER-1236 T cells to combat cancer, we commenced our Phase 1 clinical trial in May 2025 with an initial treatment target being patients suffering from relapsed, or refractory AML as well as those subsets who are positive for" https://www.sec.gov/Archives/edgar/data/1870404/000121390025066152/ea0244907-s1_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-066152): "We dosed the first patient in our Phase 1 AML clinical trial in May 2025." https://www.sec.gov/Archives/edgar/data/1870404/000121390025066152/ea0244907-s1_cero.htm

### Sep 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-11-19, last confirmed 2026-11-13.
- SEC Form 10-Q (accession 0001213900-26-119677): "In September 2025, the Company announced that it had dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML." https://www.sec.gov/Archives/edgar/data/1870404/000121390026119677/ea0311517-10q_cero.htm
- SEC Form 10-Q (accession 0001213900-26-057753): "In September 2025, the Company announced that it had dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML." https://www.sec.gov/Archives/edgar/data/1870404/000121390026057753/ea0290300-10q_cerotherap.htm
- SEC Form 10-K (accession 0001213900-26-044040): "In September 2025, the Company announced that it had dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML." https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/ea0285271-10k_cero.htm
- SEC registration statement (S-1) (accession 0001213900-25-118817): "In September 2025, the Company announced that it had dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML." https://www.sec.gov/Archives/edgar/data/1870404/000121390025118817/ea0267089-s1_cero.htm
- SEC Form 10-Q (accession 0001213900-25-112619): "In September 2025, the Company announced that it had dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML." https://www.sec.gov/Archives/edgar/data/1870404/000121390025112619/ea0263826-10q_cerotherap.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cer-1236.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CER-1236 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cer-1236

```bibtex
@misc{secapidev_pdufa_cer_1236_20261116,
  title        = {CER-1236 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cer-1236}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cer_1236_20261116","title":"CER-1236 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cer-1236","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
